SCHEMBL3226945

SCHEMBL3226945

CCN(c1nc(-c2ccc(OC)cc2)c2ccc(=O)n(-c3ccc(C(F)(F)F)cc3)c2n1)C(O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.36
CASP1 P29466 7/20 0.36
CASP7 P55210 7/20 0.36
USP2 O75604 6/20 0.36
CYP1A2 P05177 5/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
HSD17B10 Q99714 3/20 0.36
HBB P68871 3/20 0.36
BRCA1 P38398 1/20 0.36
HIF1A Q16665 5/20 0.36
CYP3A4 P08684 5/20 0.36
LMNA P02545 2/20 0.36
CYP2C19 P33261 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
CYP2D6 P10635 2/20 0.36
PPARD Q03181 6/20 0.35
CYP2C9 P11712 1/20 0.35
PTPN11 Q06124 1/20 0.35
NPBWR1 P48145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233019 0.90 TDP1 (0.39) HPGDPPARGKDM4ENPC1RAB9A
SCHEMBL3229356 0.90 MEN1 (0.35) ALDH1A1CASP1CASP7USP2CYP1A2
SCHEMBL3226952 0.89 CXCR3 (0.37) ALDH1A1CASP1CASP7USP2CYP1A2
SCHEMBL3227578 0.86 TRPA1 (0.35) ALDH1A1USP2CYP1A2MEN1KMT2A
SCHEMBL3230739 0.85 TRPV1 (0.40) HSD17B10TSHRCXCR3PPARGSMN1; SMN2
SCHEMBL3216354 0.82 CNR1 (0.37) ALDH1A1MEN1KMT2ACYP3A4CYP2C9
SCHEMBL3224069 0.82 PTGS2 (0.35) PPARG
SCHEMBL3233029 0.79 TDP1 (0.39) PTPN11HPGDCXCR3PPARGKDM4E
SCHEMBL3226615 0.78 SCN9A (0.40) ALDH1A1CASP1CASP7USP2CYP1A2
SCHEMBL3230746 0.74 TRPV1 (0.39) CXCR3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069409-A1 \"NOVEL COMPOUNDS\ GLAXO GROUP LIMITED (GB) 2010-03-18 US disclosed
US-7479558-B2 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2009-01-20 US disclosed
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives CBR3, CBR1, CYP2S1 ALDH1A1 865/4885CASP1 3556/4885CASP7 2404/4885
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives CYP2S1, CYP2F1, CBR3 ALDH1A1 366/4885CASP1 2545/4885CASP7 1934/4885
US-20100069409-A1 \"NOVEL COMPOUNDS\ MAPKAPK2, CDC42BPB, MAP4K2 ALDH1A1 4413/4885CASP1 2516/4885CASP7 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.